Since the introduction of intensified insulin therapy in order to optimize glycemic control and to reduce microvascular complications, the prevalence of obesity, other features of the metabolic syndrome and cardiovascular complications have increased dramatically [8–10]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.